ATM and neoplasm: In homologous recombination repair (HRR), the mutation of breast cancer susceptibility genes, such as BRCA1 and ATM (ataxia-telangiectasia mutated protein), leads to hypersensitivity to clinical DNA-damaging drugs, whereas various susceptibilities to chemotherapy agents of different genetic backgrounds challenge current strategies for tumor treatment.